Aarti Drugs Board Clears Employee Stock Option Plan

Up to 8,00,000 performance stock options will be issued under the new PSOP 2026.
Each option grants the right to acquire one equity share of Rs 10 face value.

Reader Takeaway: The plan incentivizes staff performance, though future issuance will cause minor equity dilution for existing shareholders.

What just happened

The Board of Directors at Aarti Drugs Ltd formally adopted the 'Aarti Drugs Limited Performance Stock Option Plan 2026' (PSOP 2026) during their meeting on August 27, 2026. This initiative is designed to retain and motivate key talent through performance-linked equity rewards, operating strictly within the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.

Why this matters

Employee stock option plans are typically used to align the long-term interests of the workforce with those of shareholders. By granting up to 8,00,000 options, the company is signaling a focus on talent retention in a competitive pharmaceutical manufacturing landscape. Investors should note that while this is a standard corporate compensation practice, it represents a potential future dilution of existing equity when the options are exercised.

What changes now

The company has moved from the board approval stage to the shareholder approval stage. The proposal will now be presented to members for final clearance at an upcoming general meeting. Investors should keep an eye on the official postal ballot or EGM notice for the specific timelines and voting requirements.

Risks to watch

As with all ESOP schemes, the primary risk for retail investors is the potential for equity dilution and the associated impact on earnings per share (EPS) once these options are vested and exercised. The performance criteria attached to these options will determine how aggressively these shares are issued over the coming years.

What to track next

Shareholders should monitor the company's future regulatory filings for the official notice of the general meeting. Details regarding the vesting schedule and performance metrics associated with the PSOP 2026 will be critical for assessing the long-term impact on the company's capital structure.